| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2008, p. 2673-2676, Vol. 52, No. 7
0066-4804/08/$08.00+0 doi:10.1128/AAC.01596-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Pfizer Inc., New York, New York 10017,1 Vicuron Pharmaceuticals, New York, New York2
Received 11 December 2007/ Returned for modification 5 February 2008/ Accepted 16 April 2008
This study assessed the tissue distribution of anidulafungin in rats. Anidulafungin rapidly distributed into tissues, achieving peak concentrations within 30 min, and maintained levels above MICs for common pathogens over 72 h. In tissues susceptible to fungal infection (liver, lung, spleen, kidney), exposure was 9- to 12-fold higher than in plasma.
Published ahead of print on 28 April 2008.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |